Claudia Goldblatt

Mrs. Claudia Goldblatt

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Sexually Transmitted Infections
Verified
Journal Article
Closed access
PDF file
CGClaudia Goldblatt
Claudia Goldblatt
MMMiranda S Moore
Miranda S Moore
KPKatherine Penrose
Katherine Penrose
SBSarah Braunstein
Sarah Braunstein
ABAngelica Bocour
Angelica Bocour
AWAnn Winters
Ann Winters
Objectives To calculate the rate of hepatitis C virus (HCV) among HIV-infected men who have sex with men (MSM) with no reported history of injection drug use (IDU), and to assess whether disparities exist in HIV/HCV coinfection by race/ethnicity and neighbourhood poverty level within this population in New York City. Methods HIV-positive men who reported sex with men and did not report IDU at the time of HIV diagnosis, diagnosed through 2015 and alive as of 2000, were matched to people with HCV first reported to the New York City Department of Health and Mental Hygiene between 2000 and 2015. Those with HCV reported before or within 90 days of HIV infection were excluded. A multivariable Cox proportional hazards model was fit to compare the association between HCV diagnosis, race/ethnicity and neighbourhood poverty level. Results From 2000 to 2015, 54 488 non-IDU MSM were diagnosed with HIV, of whom 2762 (5.1%) were diagnosed with HCV after HIV diagnosis, yielding an overall age-adjusted HCV diagnosis rate of 512 per 100 000 person-years. HIV/HCV coinfection was significantly higher among non-Latino blacks (adjusted HR (aHR)=1.24, 95% CI 1.11 to 1.40) compared with non-Latino whites and among persons living in high-poverty neighbourhoods compared with those in low-poverty neighbourhoods (aHR=1.17, 95% CI 1.01 to 1.35) after stratification by year of HIV diagnosis. Conclusion Disparities in HIV/HCV coinfection among HIV-positive MSM were observed by race/ethnicity and neighbourhood poverty level. Routine HCV screening is recommended for people infected with HIV. People coinfected with HIV and HCV should be linked to HCV care, treated and cured to reduce morbidity and mortality, and to avoid ongoing HCV transmission.

3 June 2024 in Chest
Verified
Journal Article
Closed access
DODavid Ost
David Ost
CGClaudia Goldblatt
Claudia Goldblatt
MJMolly Jung
Molly Jung
MWMia Weiss
Mia Weiss
SXShibei Xu
Shibei Xu
EEErik Erdal
Erik Erdal

17 April 2023 in Sexually Transmitted Diseases
Verified
Journal Article
Open access
CPCasey N. Pinto
Casey N. Pinto
MJMolly Jung
Molly Jung
MWMegan Mba Wimmer
Megan Mba Wimmer
CGClaudia Goldblatt
Claudia Goldblatt
NSNicole Ba Sweeney
Nicole Ba Sweeney
BPBarbara Van Der Pol
Barbara Van Der Pol
Background: Data are lacking on adherence to Centers for Disease Control and Prevention testing guidelines among insured US women presenting with vaginal health complaints; thus, we quantified vaginitis testing frequency and assessed the co-testing rate for causes of vaginitis and Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). Methods: This was a retrospective analysis of deidentified data from a medical database. Information from women aged 18 to 50 years was obtained from the Truven MarketScan Commercial Database (2012–2017) using Current Procedural Terminology (CPT) codes; χ 2 testing was applied to determine co-testing differences for CT/NG based on vaginitis test type. Odds ratios were calculated to determine the association with CT/NG screening across vaginitis testing categories. Results: Approximately 48% of 1,359,289 women received a vaginitis diagnosis that involved a laboratory-based test. Of these women, only 34% were co-tested for CT/NG. CT/NG co-testing was highest for those with nucleic acid amplification testing for vaginitis and lowest for those with no vaginitis testing CPT code (71% vs. 23%, respectively; P < 0.0001). Conclusions: The vaginitis nucleic acid amplification test, indicated by CPT code, was associated with statistically significantly higher CT/NG testing rates. Molecular diagnostics may support vaginitis testing in settings that have limited opportunities for microscopy and clinical examinations and offer greater opportunity to offer comprehensive women's health care that includes testing for chlamydia and/or gonorrhea infections.

23 August 2024 in Pharmacy
Verified
Journal Article
Open access
PDF file
KBKaren Basile
Karen Basile
MMMonserrat Martínez
Monserrat Martínez
JLJulia Lucaci
Julia Lucaci
CGClaudia Goldblatt
Claudia Goldblatt
IBIdal Beer
Idal Beer
Drug dispensing in retail pharmacies typically involves several manual tasks that often lead to inefficiencies and errors. This is the first published quality improvement study in Latin America, specifically in Brazil, investigating the operational impacts of implementing a robotic dispensing system in a retail pharmacy. Through observational techniques, we measured the time required for the following pharmacy workflows before and after implementing the robotic dispensing system: customer service, receiving stock, stocking inventory, separation, invoicing, and packaging of online orders for delivery. Time savings were observed across all workflows within the pharmacy, notably in receiving stock and online order separation, which experienced 70% and 75% reductions in total time, respectively. Furthermore, customer service, stocking, invoicing, and packaging of online orders, also saw total time reductions from 36% to 53% after implementation of the robotic dispensing system. This study demonstrates an improvement in the pharmacy’s operational efficiency post-implementation of the robotic dispensing system. These findings highlight the potential for such automated systems to streamline pharmacy operations, improve staff time efficiency, and enhance service delivery.

1 October 2026 in Hernia
Verified
Journal Article
Open access
PDF file
BPBenjamin K Poulose
Benjamin K Poulose
CGClaudia Goldblatt
Claudia Goldblatt
MWMia Weiss
Mia Weiss
MJMolly Jung
Molly Jung
CSCatherine Steele
Catherine Steele
HGHakan Gurcan
Hakan Gurcan
Purpose The modified Ventral Hernia Working Group (mVHWG) classification stratifies patients by risk for complications; however, real-world evidence quantifying complication burden across mVHWG grades remains limited. This study developed and applied a claims-based algorithm to approximate the mVHWG classification and assess variations in postoperative complication burden by mVHWG grade. Methods A retrospective cohort study was conducted using MarketScan®. Adults undergoing VHR between January 2021 and December 2024 were included if they had continuous enrollment for at least 12 months pre-procedure and 6 months post-procedure. Patients were classified into mVHWG Grades 1–3 using diagnosis and procedure codes. Postoperative complications within 6 months were identified using claims data. Incidence and number of complications per patient were assessed. Results 29,845 patients were included, classified as Grade 1 (44.4%), Grade 2 (44%), and Grade 3 (11.6%). Within 6 months, 17.2% experienced postoperative complications, with a significant stepwise increase in incidence by mVHWG grade (10.6%, 15.7% and 48.5% for Grades 1–3 respectively). The number of recorded complications per patient was higher with increased mVHWG grade. Conclusion This study operationalizes mVHWG classification in claims data and demonstrates an increase in complication burden across mVHWG grades following VHR, including higher incidence and greater number of complications per patient. Grade 2 patients represented a large proportion of the cohort and experience greater complication burden than Grade 1 patients, underscoring the importance of this risk group. Further research is warranted to validate the algorithm against clinically assigned mVHWG grades as well as to examine long-term outcomes and costs associated with early complications across mVHWG grades.